Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 28;15:1437–1456. doi: 10.2147/JIR.S348786

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Su et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Survival curves for TLR3 in IHC samples and TCGA. (A) Survival curves in IHC samples indicated that ESCC patients with low TLR3 protein expression had a shorter OS (i) and DSS (ii) than those with high-level of TLR3 (15.4 vs 26.7 months, P = 0.006; 15.4 vs 27.3 months, P = 0.003, respectively) in the IHC samples. (B) Stratified by TMN stage, i. there was no statistical significance in stage III (P = 0.635); ii, iii. the OS of stage IV or combined stage III and IV patients with high TLR3 level was significantly longer than that of patients with low TLR3 level (P = 0.024 and P = 0.025, respectively). (C) The survival curves for having received postoperative chemotherapy (i, P = 0.059) or radiotherapy (ii, P = 0.690) patients in IHC samples. (D) The survival curves of OS in the TCGA-ESCC patients. i. all the data; ii. TNM stage III (P = 0.033, HR = 0.199, 95% CI: 0.045–0.874); iii. TNM stage II. (E) ESCA patients with low TLR3 mRNA expression had a shorter OS than those with high levels of TLR3 (13.2 vs 18.3 months, P = 0.028) in the Kaplan-Meier survival curves from the TCGA.